Cancer Therapies on the Brink of Breakthrough: New Hope for Patients and Profits

Strategic Insights -

Advances in cancer therapies are giving new hope to patients and sparking optimism in the scientific community. With the development of molecular biology technologies, companies are now able to design and develop drugs that directly target cancer cells without causing side effects. This targeted approach has the potential to lead to cures for patients and massive profits for pharmaceutical companies.

Key Takeaways:

  • The war against cancer is on the brink of a major breakthrough, with breakthroughs in understanding the biology of cancer enabling the development of targeted drugs.
  • New technologies such as molecular biology and genetic engineering are allowing companies to design and develop drugs that can target cancer cells directly, reducing side effects and increasing effectiveness.
  • The pharmaceutical industry is optimistic about the potential of these new therapies, with some companies predicting sales of up to $250 million a year for targeted cancer drugs.
  • The big players in the industry, including Bristol-Myers Squibb, Zeneca, and Pharmacia & Upjohn, are investing heavily in cancer research and developing new treatments.
  • The development of Rituxan and Herceptin, two targeted cancer drugs, has proven the effectiveness of this approach and has raised hopes for new treatments.
  • Comprehensive cancer treatment packages, including palliative care and long-term care, are the most reliable way to ensure profits for companies in the cancer industry.
  • The world's population is aging, and cancer is predominantly a disease of the elderly, creating a growing demand for cancer treatments.
  • Disease management is becoming increasingly attractive to governments as a way to reduce healthcare costs, and "for-profit" medical centers may become a major player in the industry.

Statistics:

  • $9 billion: the amount spent globally on pure anti-cancer drugs.
  • 94 cents: the percentage of cancer care costs not related to drugs.
  • $8,904: the cost for one course of treatment for Rituxan.
  • $250 million: the predicted annual sales of the anti-cancer cruise missile Herceptin.
  • 10 years: the minimum lead time for new cancer drugs.
  • $400 million: the minimum research and development costs for new cancer drugs.
  • 40 years: the time since the last new drug for colorectal cancer was approved.
  • $54.2 billion: the total spent by European governments on prescription pharmaceuticals.

Sources:

  • EUCAN 90 (IARC 1996)
  • Black, R J et al, Eur J Cancer, v.33, no 7 pp1075-1107
  • "Big Pharma bets on big prizes", Philip Carter, The Banker, September 1998